Predicting progression in patients with Parkinson's disease.
作者信息
Blauwendraat Cornelis, Bandrés-Ciga Sara, Singleton Andrew B
机构信息
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA; Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Lancet Neurol. 2017 Nov;16(11):860-862. doi: 10.1016/S1474-4422(17)30331-9. Epub 2017 Sep 25.
Abstract
摘要
相似文献
1
Predicting progression in patients with Parkinson's disease.预测帕金森病患者的病情进展。
Lancet Neurol. 2017 Nov;16(11):860-862. doi: 10.1016/S1474-4422(17)30331-9. Epub 2017 Sep 25.
2
Can neuroimaging predict dementia in Parkinson's disease?神经影像学能否预测帕金森病患者的痴呆症？
Brain. 2018 Sep 1;141(9):2545-2560. doi: 10.1093/brain/awy211.
3
Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.帕金森病亚型的临床标准：生物标志物和纵向进展。
Brain. 2017 Jul 1;140(7):1959-1976. doi: 10.1093/brain/awx118.
4
COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.COPPADIS - 2015（2015年西班牙帕金森病患者队列研究），一项关于帕金森病进展的全球性前瞻性、多中心、非干预性长期研究，涵盖临床评估、血清生物标志物、基因研究和神经影像学。
BMC Neurol. 2016 Feb 25;16:26. doi: 10.1186/s12883-016-0548-9.
5
Progression marker of Parkinson's disease: a 4-year multi-site imaging study.帕金森病的进展标志物：一项为期4年的多中心影像学研究。
Brain. 2017 Aug 1;140(8):2183-2192. doi: 10.1093/brain/awx146.
6
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease.多巴胺转运体的分子神经影像学作为早期帕金森病临床试验的患者富集生物标志物。
Clin Transl Sci. 2019 May;12(3):240-246. doi: 10.1111/cts.12619. Epub 2019 Mar 18.
7
Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.预测性大数据分析：一项使用大规模、复杂、异构、不一致、多源和不完整观测数据对帕金森病的研究。
PLoS One. 2016 Aug 5;11(8):e0157077. doi: 10.1371/journal.pone.0157077. eCollection 2016.
8
Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures.使用临床和神经影像学基线测量来预测帕金森病的病程。
Parkinsonism Relat Disord. 2021 Apr;85:44-51. doi: 10.1016/j.parkreldis.2021.02.026. Epub 2021 Mar 7.
9
Parkinson's disease tremors and serotonin.帕金森病震颤与血清素
Brain. 2018 Mar 1;141(3):624-626. doi: 10.1093/brain/awx361.
10
Advances in imaging in Parkinson's disease.帕金森病影像学进展。
Lancet Neurol. 2011 Nov;10(11):987-1001. doi: 10.1016/S1474-4422(11)70214-9.
引用本文的文献
1
Quality of life and living with Parkinson's disease: a qualitative exploration within an Irish context.生活质量与帕金森病的共存：爱尔兰背景下的定性探索。
BMC Neurol. 2024 Aug 8;24(1):275. doi: 10.1186/s12883-024-03769-y.
2
The emerging postural instability phenotype in idiopathic Parkinson disease.特发性帕金森病中出现的姿势不稳表型。
NPJ Parkinsons Dis. 2022 Mar 18;8(1):28. doi: 10.1038/s41531-022-00287-x.
3
Parkinson's progression prediction using machine learning and serum cytokines.利用机器学习和血清细胞因子预测帕金森病的进展
NPJ Parkinsons Dis. 2019 Jul 25;5:14. doi: 10.1038/s41531-019-0086-4. eCollection 2019.
4
SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.SNCA 和 mTOR 通路单核苷酸多态性相互作用，调节帕金森病的发病年龄。
Mov Disord. 2019 Sep;34(9):1333-1344. doi: 10.1002/mds.27770. Epub 2019 Jun 24.
本文引用的文献
1
Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.新诊断帕金森病患者运动进展的临床和遗传预测因素的大规模识别：一项纵向队列研究及验证
Lancet Neurol. 2017 Nov;16(11):908-916. doi: 10.1016/S1474-4422(17)30328-9. Epub 2017 Sep 25.
2
Imaging genetics approach to Parkinson's disease and its correlation with clinical score.帕金森病的影像遗传学方法及其与临床评分的相关性。
Sci Rep. 2017 Apr 21;7:46700. doi: 10.1038/srep46700.
3
Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.GBA 突变与 E326K 多态性与帕金森病运动和认知进展的关联。
JAMA Neurol. 2016 Oct 1;73(10):1217-1224. doi: 10.1001/jamaneurol.2016.2245.
4
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.基于临床和基因分类的帕金森病诊断：一项基于人群的建模研究。
Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.
5
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).帕金森病进展标志物倡议（PPMI）中的基线基因关联。
Mov Disord. 2016 Jan;31(1):79-85. doi: 10.1002/mds.26374. Epub 2015 Aug 13.
6
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.多巴胺转运体显像与帕金森病的长期预后相关。
Mov Disord. 2012 Sep 15;27(11):1392-7. doi: 10.1002/mds.25157. Epub 2012 Sep 13.
7
The Parkinson Progression Marker Initiative (PPMI).帕金森进展标志物倡议（PPMI）。
Prog Neurobiol. 2011 Dec;95(4):629-35. doi: 10.1016/j.pneurobio.2011.09.005. Epub 2011 Sep 14.
8
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.帕金森病生物标志物开发的纵向研究计划：一项可行性研究。
Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690.
9
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.运动障碍协会赞助的统一帕金森病评定量表修订版（MDS-UPDRS）：量表介绍及临床测量测试结果
Mov Disord. 2008 Nov 15;23(15):2129-70. doi: 10.1002/mds.22340.
Zotero 插件